// App-Quantinova.ai

375 : Phenotypic and molecular characterization of circulating tumor cells (CTCs) in patients with castration resistant prostate cancer (CRPC) undergoing treatment with abiraterone acetate or enzalutamide

Researchers

Presenter

  • Jaymala Patel

Principal Investigators

  • Vipul Bhargava

  • Miaoling He

  • Brad Foulk

  • Denis A. Smirnov

  • Przemyslaw Twardowski

  • Marcin Kortylewski

  • Sumanta Kumar Pal

  • Jeremy O. Jones

Medical Centers

  • Medical Oncology, City of Hope, Duarte, CA

  • Janssen Pharmaceuticals, Spring House, PA

  • Department of Medical Oncology, City of Hope, Duarte, CA

  • Department of Cancer Immunotherapeutics & Tumor Immunology, City of Hope, Duarte, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • CB-7598

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved